Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Traumatic brain injury and risk of dementia at different levels of cognitive ability and education

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Disturbed sleep in cluster headache is not the result of transient processes associated with the cluster period

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cerebral autoregulatory performance and the cerebrovascular response to head-of-bed positioning in acute ischemic stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Age At Menopause: A Female Risk Factor of Stroke?

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD.

METHODS: This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale.

RESULTS: Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43-0.94; p = 0.022; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS.

CONCLUSIONS: Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume28
Issue number6
Pages (from-to)2017-2025
Number of pages9
ISSN1351-5101
DOIs
Publication statusPublished - Jun 2021

    Research areas

  • DWI, MRI, WAKE-UP

ID: 66520527